<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20230828180717&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20230828180717&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Mon, 28 Aug 2023 22:07:18 +0000</lastbuilddate>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3357. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37639276</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3357>10.1001/jamacardio.2023.3357</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639276</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>James E Udelson</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37639276</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3357</dc:identifier>
</item>
<item>
<title>Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3045. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37639265</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3045>10.1001/jamacardio.2023.3045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639265</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Milind Y Desai</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China</dc:title>
<dc:identifier>pmid:37639265</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3045</dc:identifier>
</item>
<item>
<title>Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Mavacamten has shown clinical benefits in global studies for patients with obstructive hypertrophic cardiomyopathy (oHCM), but evidence in the Asian population is lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic oHCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized, double-blind, placebo-controlled clinical trial was conducted at 12 hospitals in China. Between January 4 and August 5, 2022, patients with oHCM and a left ventricular outflow tract (LVOT) gradient of 50 mm Hg or more and New York Heart Association (NYHA) class II or III symptoms were enrolled and received treatment for 30 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized 2:1 to receive mavacamten (starting at 2.5 mg once daily) or placebo for 30 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was change in Valsalva LVOT peak gradient from baseline to week 30. Left ventricular outflow tract gradients and left ventricular ejection fraction (LVEF) were assessed by echocardiography, while left ventricular mass index (LVMI) was determined by cardiac magnetic resonance imaging. Analysis was performed on an intention-to-treat basis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 81 patients (mean [SD] age, 51.9 [11.9] years; 58 men [71.6%]) were randomized. Mavacamten demonstrated a significant improvement in the primary end point compared with placebo (least-squares mean [LSM] difference, -70.3 mm Hg; 95% CI, -89.6 to -50.9 mm Hg; 1-sided P &lt; .001). Similar trends were demonstrated for resting LVOT peak gradient (LSM difference, -55.0 mm Hg; 95% CI, -69.1 to -40.9 mm Hg). At week 30, more patients receiving mavacamten than placebo achieved a Valsalva LVOT peak gradient less than 30 mm Hg (48.1% [26 of 54] vs 3.7% [1 of 27]), less than 50 mm Hg (59.3% [32 of 54] vs 7.4% [2 of 27]), and NYHA class improvement (59.3% [32 of 54] vs 14.8% [4 of 27]). Greater improvements were also observed with mavacamten regarding the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (LSM difference, 10.2; 95% CI, 4.4-16.1), N-terminal pro-B-type natriuretic peptide level (proportion of geometric mean ratio, 0.18; 95% CI, 0.13-0.24), high-sensitivity cardiac troponin I level (proportion of geometric mean ratio, 0.34; 95% CI, 0.27-0.42), and LVMI (mean difference, -30.8 g/m2; 95% CI, -41.6 to -20.1 g/m2). Safety and tolerability were similar between mavacamten and placebo. No patients experienced LVEF less than 50%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05174416.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37639259</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3030>10.1001/jamacardio.2023.3030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639259</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Zhuang Tian</dc:creator>
<dc:creator>Liwen Li</dc:creator>
<dc:creator>Xiaoyan Li</dc:creator>
<dc:creator>Jian'an Wang</dc:creator>
<dc:creator>Qing Zhang</dc:creator>
<dc:creator>Zhanquan Li</dc:creator>
<dc:creator>Daoquan Peng</dc:creator>
<dc:creator>Ping Yang</dc:creator>
<dc:creator>Wei Ma</dc:creator>
<dc:creator>Fang Wang</dc:creator>
<dc:creator>Wei Jin</dc:creator>
<dc:creator>Xiang Cheng</dc:creator>
<dc:creator>Jing Sun</dc:creator>
<dc:creator>Yiqun Fu</dc:creator>
<dc:creator>Cheng Lyu</dc:creator>
<dc:creator>Shuyang Zhang</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37639259</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3030</dc:identifier>
</item>
<item>
<title>Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3342. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the short-term need for septal reduction therapy (SRT).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the cumulative longer-term effect of mavacamten on the need for SRT through week 56.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled, multicenter, randomized clinical trial with placebo crossover at 16 weeks, conducted from July 2020 to November 2022. Participants were recruited from 19 US HCM centers. Included in the trial were patients with obstructive HCM (New York Heart Association class III/IV) referred for SRT. Study data were analyzed April to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients initially assigned to mavacamten at baseline continued the drug for 56 weeks, and patients taking placebo crossed over to mavacamten from week 16 to week 56 (40-week exposure). Dose titrations were performed using echocardiographic LVOT gradient and LV ejection fraction (LVEF) measurements.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURE: Proportion of patients undergoing SRT, remaining guideline eligible or unevaluable SRT status at week 56.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 112 patients with highly symptomatic obstructive HCM, 108 (mean [SD] age, 60.3 [12.5] years; 54 male [50.0%]) qualified for the week 56 evaluation. At week 56, 5 of 56 patients (8.9%) in the original mavacamten group (3 underwent SRT, 1 was SRT eligible, and 1 was not SRT evaluable) and 10 of 52 patients (19.2%) in the placebo crossover group (3 underwent SRT, 4 were SRT eligible, and 3 were not SRT evaluable) met the composite end point. A total of 96 of 108 patients (89%) continued mavacamten long term. Between the mavacamten and placebo-to-mavacamten groups, respectively, after 56 weeks, there was a sustained reduction in resting (mean difference, -34.0 mm Hg; 95% CI, -43.5 to -24.5 mm Hg and -33.2 mm Hg; 95% CI, -41.9 to -24.5 mm Hg) and Valsalva (mean difference, -45.6 mm Hg; 95% CI, -56.5 to -34.6 mm Hg and -54.6 mm Hg; 95% CI, -66.0 to -43.3 mm Hg) LVOT gradients. Similarly, there was an improvement in NYHA class of 1 or higher in 51 of 55 patients (93%) in the original mavacamten group and in 37 of 51 patients (73%) in the placebo crossover group. Overall, 12 of 108 patients (11.1%; 95% CI, 5.87%-18.60%), which represents 7 of 56 patients (12.5%) in the original mavacamten group and 5 of 52 patients (9.6%) in the placebo crossover group, had an LVEF less than 50% (2 with LVEF ≤30%, one of whom died), and 9 of 12 patients (75%) continued treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04349072.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37639243</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3342>10.1001/jamacardio.2023.3342</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639243</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Milind Y Desai</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Kathy Wolski</dc:creator>
<dc:creator>Jeffrey B Geske</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Mark Sherrid</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Albree Tower-Rader</dc:creator>
<dc:creator>David Fermin</dc:creator>
<dc:creator>Srihari S Naidu</dc:creator>
<dc:creator>Nicholas G Smedira</dc:creator>
<dc:creator>Hartzell Schaff</dc:creator>
<dc:creator>Ellen McErlean</dc:creator>
<dc:creator>Christina Sewell</dc:creator>
<dc:creator>Lana Mudarris</dc:creator>
<dc:creator>Zhiqun Gong</dc:creator>
<dc:creator>Kathy Lampl</dc:creator>
<dc:creator>Amy J Sehnert</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37639243</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3342</dc:identifier>
</item>
<item>
<title>Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Patients with new-onset AF display high-risk features for HFpEF at diagnosis, emphasizing the importance of evaluating for HFpEF among symptomatic patients with AF. Patients with new-onset AF have accelerated progression in DD over time, which may identify patients with preclinical HFpEF, where preventive therapies may be tested.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad592. doi: 10.1093/eurheartj/ehad592. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are intimately associated disorders. HFpEF may be overlooked in AF when symptoms are simply attributed to dysrhythmia, and incident AF may identify patients at risk for developing diastolic dysfunction (DD). This study aimed to investigate the prevalence and incidence of DD in patients with new-onset AF compared to sinus rhythm (SR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adults with new-onset AF (n = 1,747) or SR (n = 29,623) and no structural heart disease were identified. Propensity-score matching was performed (1:3 ratio) between AF and SR based on age, sex, body mass index, and comorbidities. Severe DD (SDD) was defined by ≥3/4 abnormal parameters (medial e', medial E/e', tricuspid regurgitation velocity, left atrial volume index) and ≥moderate (MDD) by ≥2/4. Annualised changes in DD indices were determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: New-onset AF was independently associated with SDD (8% vs 3%) and ≥MDD (25% vs 16%). 62% of patients with AF had high-risk H2FPEF scores and 5% had clinically-recognised HFpEF. Over a median follow-up of 3.2 (interquartile range 1.6-5.8) years, DD progressed 2-4-fold more rapidly in those with new-onset AF (p &lt; 0.001 for all). Risk for incident DD was increased i new-onset AF [hazard ratio (95% confidence interval) 2.69 (2.19-3.32) for SDD and 1.73 (1.49-2.02) for ≥MDD].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with new-onset AF display high-risk features for HFpEF at diagnosis, emphasizing the importance of evaluating for HFpEF among symptomatic patients with AF. Patients with new-onset AF have accelerated progression in DD over time, which may identify patients with preclinical HFpEF, where preventive therapies may be tested.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37639219</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad592>10.1093/eurheartj/ehad592</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639219</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jwan A Naser</dc:creator>
<dc:creator>Eunjung Lee</dc:creator>
<dc:creator>Christopher G Scott</dc:creator>
<dc:creator>Austin M Kennedy</dc:creator>
<dc:creator>Patricia A Pellikka</dc:creator>
<dc:creator>Grace Lin</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications</dc:title>
<dc:identifier>pmid:37639219</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad592</dc:identifier>
</item>
<item>
<title>Atrial pacing and atrial fibrillation in sinus node dysfunction: a relationship that remains elusive</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad569. doi: 10.1093/eurheartj/ehad569. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638993</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad569>10.1093/eurheartj/ehad569</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638993</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ratika Parkash</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial pacing and atrial fibrillation in sinus node dysfunction: a relationship that remains elusive</dc:title>
<dc:identifier>pmid:37638993</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad569</dc:identifier>
</item>
<item>
<title>Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638973/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Atrial pacing minimization in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation. Programming a base rate of 40 bpm without rate-adaptive pacing is associated with an increased risk of syncope or presyncope.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad564. doi: 10.1093/eurheartj/ehad564. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: High percentages of atrial pacing have been associated with an increased risk of atrial fibrillation. This study aimed at evaluating whether atrial pacing minimization in patients with sinus node dysfunction reduces the incidence of atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a nationwide, randomized controlled trial, 540 patients with sinus node dysfunction and an indication for first pacemaker implantation were assigned to pacing programmed to a base rate of 60 bpm and rate-adaptive pacing (DDDR-60) or pacing programmed to a base rate of 40 bpm without rate-adaptive pacing (DDD-40). Patients were followed on remote monitoring for 2 years. The primary endpoint was time to first episode of atrial fibrillation longer than 6 min. Secondary endpoints included longer episodes of atrial fibrillation, and the safety endpoint comprised a composite of syncope or presyncope.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median percentage of atrial pacing was 1% in patients assigned to DDD-40 and 49% in patients assigned to DDDR-60. The primary endpoint occurred in 124 patients (46%) in each treatment group (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.76-1.25, P=0.83). There were no between-group differences in atrial fibrillation exceeding 6- or 24 hours, persistent atrial fibrillation, or cardioversions for atrial fibrillation. The incidence of syncope or presyncope was higher in patients assigned to DDD-40 (HR 1.71 95% CI 1.13-2.59, P=0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Atrial pacing minimization in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation. Programming a base rate of 40 bpm without rate-adaptive pacing is associated with an increased risk of syncope or presyncope.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638973/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638973</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad564>10.1093/eurheartj/ehad564</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638973</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mads Brix Kronborg</dc:creator>
<dc:creator>Maria Hee Jung Park Frausing</dc:creator>
<dc:creator>Jerzy Malczynski</dc:creator>
<dc:creator>Sam Riahi</dc:creator>
<dc:creator>Jens Haarbo</dc:creator>
<dc:creator>Katja Fiedler Holm</dc:creator>
<dc:creator>Charlotte Ellen Larroudé</dc:creator>
<dc:creator>Andi Eie Albertsen</dc:creator>
<dc:creator>Lene Svendstrup</dc:creator>
<dc:creator>Ulrik Hintze</dc:creator>
<dc:creator>Ole Dyg Pedersen</dc:creator>
<dc:creator>Ulla Davidsen</dc:creator>
<dc:creator>Thomas Fischer</dc:creator>
<dc:creator>Jens Brock Johansen</dc:creator>
<dc:creator>Jens Kristensen</dc:creator>
<dc:creator>Christian Gerdes</dc:creator>
<dc:creator>Jens Cosedis Nielsen</dc:creator>
<dc:creator>DANPACE II Investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial</dc:title>
<dc:identifier>pmid:37638973</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad564</dc:identifier>
</item>
<item>
<title>Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638968/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>Background: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis (DVT) in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events, however, it could also increase the risk of bleeding. Methods: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned cancer patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 28. doi: 10.1161/CIRCULATIONAHA.123.066360. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis (DVT) in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events, however, it could also increase the risk of bleeding. <b>Methods:</b> In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned cancer patients with isolated distal DVT, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary endpoint was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary endpoint was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary endpoint. <b>Results:</b> From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of DVT at baseline. The primary endpoint of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03 to 0.44). The major secondary endpoint of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75 to 2.41). The prespecified subgroups did not affect the estimates on the primary endpoint. <b>Conclusions:</b> In cancer patients with isolated distal DVT, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638968</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066360>10.1161/CIRCULATIONAHA.123.066360</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638968</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Yugo Yamashita</dc:creator>
<dc:creator>Takeshi Morimoto</dc:creator>
<dc:creator>Nao Muraoka</dc:creator>
<dc:creator>Takuya Oyakawa</dc:creator>
<dc:creator>Michihisa Umetsu</dc:creator>
<dc:creator>Daijirou Akamatsu</dc:creator>
<dc:creator>Yuji Nishimoto</dc:creator>
<dc:creator>Yukihito Sato</dc:creator>
<dc:creator>Takuma Takada</dc:creator>
<dc:creator>Kentaro Jujo</dc:creator>
<dc:creator>Yuichiro Minami</dc:creator>
<dc:creator>Yoshito Ogihara</dc:creator>
<dc:creator>Kaoru Dohi</dc:creator>
<dc:creator>Masashi Fujita</dc:creator>
<dc:creator>Tatsuya Nishikawa</dc:creator>
<dc:creator>Nobutaka Ikeda</dc:creator>
<dc:creator>Go Hashimoto</dc:creator>
<dc:creator>Kazunori Otsui</dc:creator>
<dc:creator>Kenta Mori</dc:creator>
<dc:creator>Daisuke Sueta</dc:creator>
<dc:creator>Yukari Tsubata</dc:creator>
<dc:creator>Masaaki Shoji</dc:creator>
<dc:creator>Ayumi Shikama</dc:creator>
<dc:creator>Yutaka Hosoi</dc:creator>
<dc:creator>Yasuhiro Tanabe</dc:creator>
<dc:creator>Ryuki Chatani</dc:creator>
<dc:creator>Kengo Tsukahara</dc:creator>
<dc:creator>Naohiko Nakanishi</dc:creator>
<dc:creator>Kitae Kim</dc:creator>
<dc:creator>Satoshi Ikeda</dc:creator>
<dc:creator>Makoto Mo</dc:creator>
<dc:creator>Yusuke Yoshikawa</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>ONCO DVT Study Investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37638968</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066360</dc:identifier>
</item>
<item>
<title>Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The quantity and quality of publicly available data from prospective clinical investigations across selected categories of cardiovascular devices, before and after CE approval during the period 2000-2021, was deemed insufficient. The majority of studies were non-randomized, with increased risk of bias, and performed in small populations without provision of power calculations, and none of the reviewed devices had randomized trial results published prior to CE mark certification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad567. doi: 10.1093/eurheartj/ehad567. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The European Union Medical Device Regulation 2017/745 challenges key stakeholders to follow transparent and rigorous approaches to the clinical evaluation of medical devices. The purpose of this study is a systematic evaluation of published clinical evidence underlying selected high-risk cardiovascular medical devices before and after market access in the European Union (CE marking) between 2000 and 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Prespecified strategies were applied to identify published studies of prospective design evaluating 71 high-risk cardiovascular devices in 7 different classes (bioresorbable coronary scaffolds, left atrial appendage occlusion devices, transcatheter aortic valve implantation systems, transcatheter mitral valve repair/replacement systems, surgical aortic and mitral heart valves, leadless pacemakers, subcutaneous implantable cardioverter-defibrillator). The search time-span covered 20 years (2000-2021). Details of study design, patient population, intervention(s) and primary outcome(s) were summarized, and assessed with respect to timing of the corresponding CE-mark approval.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At least one prospective clinical trial was identified for 70% (50/71) of the prespecifed devices. Overall, 473 reports of 308 prospectively designed studies (enrolling 97,886 individuals) were deemed eligible, including 81% (251/308) prospective non-randomized clinical trials (66,186 individuals) and 19% (57/308) randomized clinical trials (31,700 individuals). Preregistration of the study protocol was available in 49% (150/308) studies, and 16% (48/308) had a peer-reviewed publicly available protocol. Device-related adverse events were evaluated in 82% (253/308) of studies. An outcome adjudication process was reported in 39% (120/308) of the studies. Sample size was larger for randomized in comparison to non-randomized trials (median of 304 versus 100 individuals, p&lt;0.001). No randomized clinical trial published before CE-mark approval for any of the devices was identified. Non-randomized clinical trials were predominantly published after the corresponding CE-mark approval of the device under evaluation (89%, 224/251). Sample sizes were smaller for studies published before (median of 34 individuals) than after (median of 135 individuals) CE-mark approval (p&lt;0.001). Clinical trials with larger sample sizes (>;50 individuals) and those with longer recruitment periods were more likely to be published after CE-mark approval, and were more frequent during the period 2016-2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The quantity and quality of publicly available data from prospective clinical investigations across selected categories of cardiovascular devices, before and after CE approval during the period 2000-2021, was deemed insufficient. The majority of studies were non-randomized, with increased risk of bias, and performed in small populations without provision of power calculations, and none of the reviewed devices had randomized trial results published prior to CE mark certification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638967</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad567>10.1093/eurheartj/ehad567</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638967</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>George Cm Siontis</dc:creator>
<dc:creator>Bernadette Coles</dc:creator>
<dc:creator>Jonas D Häner</dc:creator>
<dc:creator>Laurna McGovern</dc:creator>
<dc:creator>Joanna Bartkowiak</dc:creator>
<dc:creator>J J Coughlan</dc:creator>
<dc:creator>Alessandro Spirito</dc:creator>
<dc:creator>Roberto Galea</dc:creator>
<dc:creator>Andreas Haeberlin</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Daijiro Tomii</dc:creator>
<dc:creator>Tom Melvin</dc:creator>
<dc:creator>André Frenk</dc:creator>
<dc:creator>Robert A Byrne</dc:creator>
<dc:creator>Alan G Fraser</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>CORE-MD investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium</dc:title>
<dc:identifier>pmid:37638967</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad567</dc:identifier>
</item>
<item>
<title>Type A aortic dissection: optimal annual case volume for surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Using this novel approach, the optimal hospital case volume threshold was statistically determined. Centralization of ATAAD care to high-volume centres may lead to improved outcomes. This method can be applied to various other cardiovascular procedures requiring centralization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad551. doi: 10.1093/eurheartj/ehad551. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The current study proposes a novel volume-outcome (V-O) meta-analytical approach to determine the optimal annual hospital case volume threshold for cardiovascular interventions in need of centralization. This novel method is applied to surgery for acute type A aortic dissection (ATAAD) as an illustrative example.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A systematic search was applied to three electronic databases (January 1st 2012 - March 29th 2023). The primary outcome was early mortality in relation to annual hospital case volume. Data were presented by volume quartiles (Qs). Restricted cubic splines were used to demonstrate the V-O relation, and the elbow method was applied to determine the optimal case volume. For clinical interpretation, numbers needed to treat (NNT) were calculated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 140 studies were included, comprising 38276 patients. A significant non-linear V-O effect was observed (p&lt;0.001), with a significant between-quartile difference for early mortality (10.3% [Q4] vs. 16.2% [Q1], p&lt;0.001). The optimal annual case volume was determined at 38 cases/year (95% CI 37-40 cases/year, NNT to save a life in a centre with the optimal volume vs. 10 cases/year = 21). More pronounced between-quartile survival differences were observed for long-term survival (10-year survival [Q4] 69% vs. [Q1] 51%, p&lt;0.001, adjusted HR 0.83, 95% CI 0.75-0.91 per quartile, NNT to save a life in a high-volume [Q4] vs. low-volume centre [Q1) = 6).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Using this novel approach, the optimal hospital case volume threshold was statistically determined. Centralization of ATAAD care to high-volume centres may lead to improved outcomes. This method can be applied to various other cardiovascular procedures requiring centralization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638786</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad551>10.1093/eurheartj/ehad551</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638786</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael J Kawczynski</dc:creator>
<dc:creator>Sander M J van Kuijk</dc:creator>
<dc:creator>Jules R Olsthoorn</dc:creator>
<dc:creator>Jos G Maessen</dc:creator>
<dc:creator>Suzanne Kats</dc:creator>
<dc:creator>Elham Bidar</dc:creator>
<dc:creator>Samuel Heuts</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Type A aortic dissection: optimal annual case volume for surgery</dc:title>
<dc:identifier>pmid:37638786</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad551</dc:identifier>
</item>
<item>
<title>Acute type A aortic dissection: stay and play or load and run?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad517. doi: 10.1093/eurheartj/ehad517. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad517>10.1093/eurheartj/ehad517</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638778</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Tim Berger</dc:creator>
<dc:creator>Maximilian Kreibich</dc:creator>
<dc:creator>Martin Czerny</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acute type A aortic dissection: stay and play or load and run?</dc:title>
<dc:identifier>pmid:37638778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad517</dc:identifier>
</item>
<item>
<title>Recommendations for statin management in primary prevention: disparities among international risk scores</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638490/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: Risk algorithms differ substantially in their estimation of risk, recommendations for statin treatment, and use of ancillary testing, even in identical patients. These results highlight the limitations of currently used risk-based approaches for addressing lipid-specific risk in primary prevention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad539. doi: 10.1093/eurheartj/ehad539. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Statin recommendations in primary prevention depend upon risk algorithms. Moreover, with intermediate risk, risk enhancers and de-enhancers are advocated to aid decisions. The aim of this study was to compare algorithms used in North America and Europe for the identification of patients warranting statin or consideration of risk enhancers and de-enhancers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A simulated population (n = 7680) equal in males and females, with/without smoking, aged 45-70 years, total cholesterol 3.5-7.0 mmol/L, high-density lipoprotein cholesterol 0.6-2.2 mmol/L, and systolic blood pressure 100-170 mmHg, was evaluated. High, intermediate, and low risks were determined using the Framingham Risk Score (FRS), Pooled Cohort Equation (PCE), four versions of Systematic Coronary Risk Evaluation 2 (SCORE2), and Multi-Ethnic Study of Atherosclerosis (MESA) algorithm (0-1000 Agatston Units).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Concordance for the three levels of risk varied from 19% to 85%. Both sexes might be considered to have low, intermediate, or high risk depending on the algorithm applied, even with the same burden of risk factors. Only SCORE2 (High Risk and Very High Risk versions) identified equal proportions of males and females with high risk. Excluding MESA, the proportion with moderate risk was 25% (SCORE2, Very High Risk Region), 32% (FRS), 39% (PCE), and 45% (SCORE2, Low Risk Region).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Risk algorithms differ substantially in their estimation of risk, recommendations for statin treatment, and use of ancillary testing, even in identical patients. These results highlight the limitations of currently used risk-based approaches for addressing lipid-specific risk in primary prevention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638490/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638490</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad539>10.1093/eurheartj/ehad539</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638490</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>G B John Mancini</dc:creator>
<dc:creator>Arnold Ryomoto</dc:creator>
<dc:creator>Eunice Yeoh</dc:creator>
<dc:creator>Liam R Brunham</dc:creator>
<dc:creator>Robert A Hegele</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Recommendations for statin management in primary prevention: disparities among international risk scores</dc:title>
<dc:identifier>pmid:37638490</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad539</dc:identifier>
</item>
<item>
<title>Cardioprotective and Anti-Inflammatory Effects of FAM3D in Myocardial Ischemia-Reperfusion Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 28. doi: 10.1161/CIRCRESAHA.123.322640. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638415</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322640>10.1161/CIRCRESAHA.123.322640</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638415</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>James Rhee</dc:creator>
<dc:creator>Rebecca Freeman</dc:creator>
<dc:creator>Kangsan Roh</dc:creator>
<dc:creator>Margaret Lyons</dc:creator>
<dc:creator>Chunyang Xiao</dc:creator>
<dc:creator>Daniel Zlotoff</dc:creator>
<dc:creator>Ashish Yeri</dc:creator>
<dc:creator>Haobo Li</dc:creator>
<dc:creator>Justin Guerra</dc:creator>
<dc:creator>J Sawalla Guseh</dc:creator>
<dc:creator>Alexandra Kuznetsov</dc:creator>
<dc:creator>Nicholas Houstis</dc:creator>
<dc:creator>Jason Roh</dc:creator>
<dc:creator>Federico Damilano</dc:creator>
<dc:creator>Xiaojun Liu</dc:creator>
<dc:creator>Michael Silverman</dc:creator>
<dc:creator>Raymond Kwong</dc:creator>
<dc:creator>Saumya Das</dc:creator>
<dc:creator>Anthony Rosenzweig</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cardioprotective and Anti-Inflammatory Effects of FAM3D in Myocardial Ischemia-Reperfusion Injury</dc:title>
<dc:identifier>pmid:37638415</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322640</dc:identifier>
</item>
<item>
<title>Skin lesions, weight loss, and ventricular tachycardia: connecting the dots to diagnose multisystemic sarcoidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638411/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad501. doi: 10.1093/eurheartj/ehad501. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638411/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638411</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad501>10.1093/eurheartj/ehad501</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638411</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Esther Papiol</dc:creator>
<dc:creator>Pablo Pastor</dc:creator>
<dc:creator>Eva Pueo</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Skin lesions, weight loss, and ventricular tachycardia: connecting the dots to diagnose multisystemic sarcoidosis</dc:title>
<dc:identifier>pmid:37638411</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad501</dc:identifier>
</item>
<item>
<title>Identification of Human Ventricular Tachycardia Demarcated by Fixed Lines of Conduction Block in a 3-Dimensional Hyperboloid Circuit</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638389/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The majority of VT circuit boundaries can be identified as fixed LOBs from intrinsic or paced activation during sinus rhythm. Analysis of activation while pacing within the scar substrate is a novel technique that may unmask concealed LOBs, previously interpreted to be functional in nature. An LOB from the perspective of a myocardial surface is frequently associated with intramural conduction, supporting the existence of a 3D hyperboloid VT circuit structure. Catheter ablation may...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 28. doi: 10.1161/CIRCULATIONAHA.123.065525. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The circuit boundaries for reentrant ventricular tachycardia (VT) have been historically conceptualized within a 2-dimensional (2D) construct, with their fixed or functional nature unresolved. This study aimed to examine the correlation between localized lines of conduction block (LOBs) evident during baseline rhythm with lateral isthmus boundaries that 3-dimensionally constrain the VT isthmus as a hyperboloid structure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 175 VT activation maps were correlated with isochronal late activation maps during baseline rhythm in 106 patients who underwent catheter ablation for scar-related VT from 3 centers (42% nonischemic cardiomyopathy). An overt LOB was defined by a deceleration zone with split potentials (≥20 ms isoelectric segment) during baseline rhythm. A novel application of pacing within deceleration zone (≥600 ms) was implemented to unmask a concealed LOB not evident during baseline rhythm. LOBs identified during baseline rhythm or pacing were correlated with isthmus boundaries during VT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 202 deceleration zones analyzed during baseline rhythm, an overt LOB was evident in 47%. When differential pacing was performed in 38 deceleration zones without overt LOBs, an underlying concealed LOB was exposed in 84%. In 152 VT activation maps (2D=53, 3-dimensional [3D]=99), 69% of lateral boundaries colocalized with an LOB in 2D activation patterns, and the depth boundary during 3D VT colocalized with an LOB in 79%. In VT circuits with isthmus regions that colocalized with a U-shaped LOB (n=28), the boundary invariably served as both lateral boundaries in 2D and 3D. Overall, 74% of isthmus boundaries were identifiable as fixed LOBs during baseline rhythm or differential pacing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The majority of VT circuit boundaries can be identified as fixed LOBs from intrinsic or paced activation during sinus rhythm. Analysis of activation while pacing within the scar substrate is a novel technique that may unmask concealed LOBs, previously interpreted to be functional in nature. An LOB from the perspective of a myocardial surface is frequently associated with intramural conduction, supporting the existence of a 3D hyperboloid VT circuit structure. Catheter ablation may be simplified to targeting both sides around an identified LOB during sinus rhythm.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638389/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37638389</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065525>10.1161/CIRCULATIONAHA.123.065525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638389</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Takuro Nishimura</dc:creator>
<dc:creator>Nathan Shatz</dc:creator>
<dc:creator>Peter Weiss</dc:creator>
<dc:creator>Michael Zawaneh</dc:creator>
<dc:creator>Rong Bai</dc:creator>
<dc:creator>Andrew D Beaser</dc:creator>
<dc:creator>Gaurav A Upadhyay</dc:creator>
<dc:creator>Zaid A Aziz</dc:creator>
<dc:creator>Hemal M Nayak</dc:creator>
<dc:creator>Dalise Y Shatz</dc:creator>
<dc:creator>Shinsuke Miyazaki</dc:creator>
<dc:creator>Masahiko Goya</dc:creator>
<dc:creator>Tetsuo Sasano</dc:creator>
<dc:creator>Wilber Su</dc:creator>
<dc:creator>Michael Raiman</dc:creator>
<dc:creator>Roderick Tung</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Identification of Human Ventricular Tachycardia Demarcated by Fixed Lines of Conduction Block in a 3-Dimensional Hyperboloid Circuit</dc:title>
<dc:identifier>pmid:37638389</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065525</dc:identifier>
</item>
<item>
<title>Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to &amp;lt;25ml/min/1.73m&lt;sup>;2&lt;/sup>;</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Patients with deterioration of kidney function below eGFR 25ml/min/1.73m² had elevated risks of CV outcomes yet appeared to benefit from continuation of dapagliflozin with no excess in safety outcomes between treatment groups. The benefit-to-risk ratio may favor continuation of dapagliflozin treatment in patients with HF experiencing deterioration of kidney function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 23:S0735-1097(23)06532-4. doi: 10.1016/j.jacc.2023.08.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: SGLT-2 inhibitors are guideline-recommended in the management of heart failure(HF). While these therapies can be initiated even in patients with comorbid CKD, some patients may face deterioration in kidney function over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To examine the safety and efficacy of continuing SGLT-2 inhibitors in HF when eGFR falls below thresholds for initiation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Associations between a deterioration in eGFR below 25 ml/min/1.73m<sup>2</sup> , efficacy and safety outcomes, and treatment with dapagliflozin were evaluated in time-updated Cox proportional hazards models in a participant-level pooled analysis of DAPA-HF and DELIVER.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 11,007 patients, 347 (3.2%) experienced a deterioration in eGFR to &lt;25ml/min/1.73m<sup>2</sup> at least once in follow-up. These patients had a higher risk of the primary composite outcome (HR 1.87; 95% CI: 1.48-2.35, p&lt;0.001). The risk of the primary outcome was lower with dapagliflozin compared with placebo both among patients who did (HR 0.53; 95% CI: 0.33-0.83) and did not (HR 0.78; 95% CI: 0.72-0.86) experience deterioration in kidney function below eGFR&lt;25ml/min/1.73m<sup>2</sup> (P<sub>interaction</sub>=0.17). The risk of safety outcomes including drug discontinuation were higher among patients with deterioration in eGFR&lt;25ml/min/1.73m<sup>2</sup> ; however, rates remained similar between treatment groups including among those who remained on study drug.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with deterioration of kidney function below eGFR 25ml/min/1.73m<sup>2</sup> had elevated risks of CV outcomes yet appeared to benefit from continuation of dapagliflozin with no excess in safety outcomes between treatment groups. The benefit-to-risk ratio may favor continuation of dapagliflozin treatment in patients with HF experiencing deterioration of kidney function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37634707</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.026>10.1016/j.jacc.2023.08.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634707</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Lars Kober</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Bela Merkely</dc:creator>
<dc:creator>Magnus Petersson</dc:creator>
<dc:creator>Anna Maria Langkilde</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to &amp;lt;25ml/min/1.73m&lt;sup>;2&lt;/sup>;</dc:title>
<dc:identifier>pmid:37634707</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.026</dc:identifier>
</item>
<item>
<title>Coronary Flow Capacity And Survival Prediction After Revascularization: Physiological Basis And Clinical Implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Severely reduced CFC and associated Observed survival probability improved after first and repeat revascularization compared with no revascularization for comparable CFC severity. Non-severe CFC showed no benefit. Discordance between Observed actual and Virtual hypothetical post=revascularization survival probability revealed residual CAD or failed revascularization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad579. doi: 10.1093/eurheartj/ehad579. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Coronary Flow Capacity (CFC) associates with an Observed 10-yearsurvival probability for individual patients before and after actual revascularization for comparison to Virtual hypothetical ideal complete revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Stress myocardial perfusion (mL/min/g) and coronary flow reserve (CFR) per pixel were quantified in 6979 coronary artery disease (CAD) subjects using Rb-82 positron emission tomography (PET) for CFC maps of artery-specific size-severity abnormalities expressed as percent left ventricle (%LV) with prospective follow-up to define survival probability per-decade as fraction of 1.0.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Severely reduced CFC in 6979 subjects predicted low survival probability that improved by 42% after revascularization compared with no revascularization for comparable severity (P=0.0015). For 283 pre-and-post-procedure PET pairs, severely reduced regional CFC-associated survival probability improved heterogeneously after revascularization (P&lt;0.001), more so after bypass surgery than percutaneous coronary interventions (P&lt;0.001) but normalized in only 5.7%; non-severe baseline CFC or survival probability did not improve compared with severe CFC (P=0.00001). Observed CFC=associated survival probability after actual revascularization was lower than Virtual ideal hypothetical complete post-revascularization survival probability due to residual CAD or failed revascularization (P&lt;0.001) unrelated to gender or microvascular dysfunction. Severely reduced CFC in 2552 post-revascularization subjects associated with low survival probability also improved after repeat revascularization compared with no repeat procedures (P=0.025).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Severely reduced CFC and associated Observed survival probability improved after first and repeat revascularization compared with no revascularization for comparable CFC severity. Non-severe CFC showed no benefit. Discordance between Observed actual and Virtual hypothetical post=revascularization survival probability revealed residual CAD or failed revascularization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37634192</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad579>10.1093/eurheartj/ehad579</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634192</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>K Lance Gould</dc:creator>
<dc:creator>Nils P Johnson</dc:creator>
<dc:creator>Amanda E Roby</dc:creator>
<dc:creator>Linh Bui</dc:creator>
<dc:creator>Danai Kitkungvan</dc:creator>
<dc:creator>Monica B Patel</dc:creator>
<dc:creator>Tung Nguyen</dc:creator>
<dc:creator>Richard Kirkeeide</dc:creator>
<dc:creator>Mary Haynie</dc:creator>
<dc:creator>Salman A Arain</dc:creator>
<dc:creator>Konstantinos Charitakis</dc:creator>
<dc:creator>Abhijeet Dhoble</dc:creator>
<dc:creator>Richard Smalling</dc:creator>
<dc:creator>Angelo Nascimbene</dc:creator>
<dc:creator>Marwan Jumean</dc:creator>
<dc:creator>Sachin Kumar</dc:creator>
<dc:creator>Biswajit Kar</dc:creator>
<dc:creator>Stefano Sdringola</dc:creator>
<dc:creator>Anthony Estrera</dc:creator>
<dc:creator>Igor Gregoricm</dc:creator>
<dc:creator>Dejian Lai</dc:creator>
<dc:creator>Ruosha Li</dc:creator>
<dc:creator>David McPherson</dc:creator>
<dc:creator>Jagat Narula</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary Flow Capacity And Survival Prediction After Revascularization: Physiological Basis And Clinical Implications</dc:title>
<dc:identifier>pmid:37634192</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad579</dc:identifier>
</item>
<item>
<title>Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement (TAVR-CMR): A Randomized, Open-Label, Non-Inferiority Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>Background: Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, as a sizable proportion of TAVR candidates have chronic kidney disease (CKD), the use of iodinated contrast media is a limitation. Cardiac magnetic resonance (CMR) is a promising alternative, yet randomized data comparing the effectiveness of CMR- versus CT-guided TAVR are lacking. Methods: An investigator-initiated, prospective, randomized, open-label, non-inferiority trial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 27. doi: 10.1161/CIRCULATIONAHA.123.066498. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, as a sizable proportion of TAVR candidates have chronic kidney disease (CKD), the use of iodinated contrast media is a limitation. Cardiac magnetic resonance (CMR) is a promising alternative, yet randomized data comparing the effectiveness of CMR- versus CT-guided TAVR are lacking. <b>Methods:</b> An investigator-initiated, prospective, randomized, open-label, non-inferiority trial was conducted at two Austrian heart centers. Patients evaluated for TAVR according to the inclusion (severe symptomatic aortic stenosis) and exclusion criteria (contraindication to CMR, CT, or TAVR, a life expectancy &lt; 1 year, CKD 4 or 5) were randomized (1:1) to undergo CMR- or CT-guiding. The primary outcome was defined according to the Valve Academic Research Consortium-2 definition of implantation success at discharge, including absence of procedural mortality, correct positioning of a single prosthetic valve, and proper prosthetic valve performance. Non-inferiority was assessed using a hybrid modified intention-to-treat (mITT)/per-protocol (PP) approach based on an absolute risk difference margin of 9%. <b>Results:</b> Between September 11, 2017, and December 16, 2022, 380 candidates for TAVR were randomized to CMR-guided (191 patients) or CT-guided (189 patients) TAVR planning. Of these, 138 patients (72.3%) in the CMR-guided group and 129 patients (68.3%) in the CT-guided group eventually underwent TAVR (mITT cohort). Of these 267, 19 patients had protocol deviations, resulting in a PP cohort of 248 patients (n=121 CMR-guided, n=127 CT-guided). In the mITT cohort, implantation success was achieved in 129 patients (93.5%) in the CMR group and in 117 patients (90.7%) in the CT group (between-group difference, 2.8%; 90% confidence interval [CI]: -2.7 to 8.2%; p&lt;0.01 for non-inferiority). In the PP cohort (n=248), the between-group difference was 2.0% (90% CI: -3.8 to 7.8%; p&lt;0.01 for non-inferiority). <b>Conclusions:</b> CMR-guided TAVR was non-inferior to CT-guided TAVR in terms of device implantation success. CMR can therefore be considered as an alternative for TAVR planning.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37634187</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066498>10.1161/CIRCULATIONAHA.123.066498</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634187</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Martin Reindl</dc:creator>
<dc:creator>Ivan Lechner</dc:creator>
<dc:creator>Magdalena Holzknecht</dc:creator>
<dc:creator>Christina Tiller</dc:creator>
<dc:creator>Priscilla Fink</dc:creator>
<dc:creator>Fritz Oberhollenzer</dc:creator>
<dc:creator>Sebastian von der Emde</dc:creator>
<dc:creator>Mathias Pamminger</dc:creator>
<dc:creator>Felix Troger</dc:creator>
<dc:creator>Christian Kremser</dc:creator>
<dc:creator>Elisabeth Laßnig</dc:creator>
<dc:creator>Kathrin Danninger</dc:creator>
<dc:creator>Ronald K Binder</dc:creator>
<dc:creator>Hanno Ulmer</dc:creator>
<dc:creator>Christoph Brenner</dc:creator>
<dc:creator>Gert Klug</dc:creator>
<dc:creator>Axel Bauer</dc:creator>
<dc:creator>Bernhard Metzler</dc:creator>
<dc:creator>Agnes Mayr</dc:creator>
<dc:creator>Sebastian Johannes Reinstadler</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement (TAVR-CMR): A Randomized, Open-Label, Non-Inferiority Trial</dc:title>
<dc:identifier>pmid:37634187</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066498</dc:identifier>
</item>
<item>
<title>Instantaneous wave-free ratio compared to fractional flow reserve: time for rethinking current recommendations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634167/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad574. doi: 10.1093/eurheartj/ehad574. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634167/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37634167</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad574>10.1093/eurheartj/ehad574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634167</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mirvat Alasnag</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Instantaneous wave-free ratio compared to fractional flow reserve: time for rethinking current recommendations</dc:title>
<dc:identifier>pmid:37634167</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad574</dc:identifier>
</item>
<item>
<title>Coronary revascularization guided by instantaneous wave-free ratio compared to fractional flow reserve: pooled 5-year mortality in the DEFINE-FLAIR and iFR-SWEDEHEART trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad552. doi: 10.1093/eurheartj/ehad552. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37634165</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad552>10.1093/eurheartj/ehad552</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634165</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>John D McClure</dc:creator>
<dc:creator>Keith G Oldroyd</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary revascularization guided by instantaneous wave-free ratio compared to fractional flow reserve: pooled 5-year mortality in the DEFINE-FLAIR and iFR-SWEDEHEART trials</dc:title>
<dc:identifier>pmid:37634165</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad552</dc:identifier>
</item>
<item>
<title>New-onset atrial fibrillation in chronic coronary syndrome: the CLARIFY registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230828180717&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Among CCS patients, NOAF is common and is strongly associated with worse outcomes. Whether more intensive preventive measures and more systematic screening for AF would improve prognosis in this population deserves further investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad556. doi: 10.1093/eurheartj/ehad556. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Data on new-onset atrial fibrillation (NOAF) in patients with chronic coronary syndromes (CCS) are scarce. This study aims to describe the incidence, predictors and impact on cardiovascular outcomes of NOAF in CCS patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from the international (45 countries) CLARIFY registry (prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) were used. Among 29,001 CCS outpatients without previously reported AF at baseline, patients with at least one episode of AF/flutter diagnosed during 5-year follow-up were compared with patients in sinus rhythm throughout the study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The incidence rate of NOAF was 1.12 [95% confidence interval (CI) 1.06-1.18] per 100 patient-years (cumulative incidence at 5 years: 5.0%). Independent predictors of NOAF were increasing age, increasing body mass index, low estimated glomerular filtration rate, Caucasian ethnicity, alcohol intake and low left ventricular ejection fraction, while high triglycerides were associated with lower incidence. NOAF was associated with a substantial increase in the risk of adverse outcomes, with adjusted hazard ratios of 2.01 (95% CI 1.61-2.52) for the composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, 2.61 (95% CI 2.04-3.34) for cardiovascular death, 1.64 (95% CI 1.07-2.50) for non-fatal myocardial infarction, 2.27 (95% CI 1.85-2.78) for all-cause death, 8.44 (95% CI 7.05-10.10) for hospitalization for heart failure and 4.46 (95% CI 2.85-6.99) for major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among CCS patients, NOAF is common and is strongly associated with worse outcomes. Whether more intensive preventive measures and more systematic screening for AF would improve prognosis in this population deserves further investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230828180717&v=2.17.9.post6+86293ac">37634147</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad556>10.1093/eurheartj/ehad556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634147</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alexandre Gautier</dc:creator>
<dc:creator>Fabien Picard</dc:creator>
<dc:creator>Gregory Ducrocq</dc:creator>
<dc:creator>Yedid Elbez</dc:creator>
<dc:creator>Kim M Fox</dc:creator>
<dc:creator>Roberto Ferrari</dc:creator>
<dc:creator>Ian Ford</dc:creator>
<dc:creator>Jean-Claude Tardif</dc:creator>
<dc:creator>Michal Tendera</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New-onset atrial fibrillation in chronic coronary syndrome: the CLARIFY registry</dc:title>
<dc:identifier>pmid:37634147</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad556</dc:identifier>
</item>





























</channel>
</rss>